These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32362193)

  • 1. Quadruple therapy for asymptomatic COVID-19 infection patients.
    Wang L; Xu X; Ruan J; Lin S; Jiang J; Ye H
    Expert Rev Anti Infect Ther; 2020 Jul; 18(7):617-624. PubMed ID: 32362193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
    Wang N; Zhan Y; Zhu L; Hou Z; Liu F; Song P; Qiu F; Wang X; Zou X; Wan D; Qian X; Wang S; Guo Y; Yu H; Cui M; Tong G; Xu Y; Zheng Z; Lu Y; Hong P
    Cell Host Microbe; 2020 Sep; 28(3):455-464.e2. PubMed ID: 32707096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol.
    Zeng YM; Xu XL; He XQ; Tang SQ; Li Y; Huang YQ; Harypursat V; Chen YK
    Chin Med J (Engl); 2020 May; 133(9):1132-1134. PubMed ID: 32149772
    [No Abstract]   [Full Text] [Related]  

  • 4. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.
    Zhu Z; Lu Z; Xu T; Chen C; Yang G; Zha T; Lu J; Xue Y
    J Infect; 2020 Jul; 81(1):e21-e23. PubMed ID: 32283143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
    Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J
    J Infect; 2020 Jul; 81(1):e1-e5. PubMed ID: 32171872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.
    Liu X; Chen H; Shang Y; Zhu H; Chen G; Chen Y; Liu S; Zhou Y; Huang M; Hong Z; Xia J
    Trials; 2020 Jul; 21(1):622. PubMed ID: 32641091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET 1: Lopinavir-ritonavir and COVID-19.
    Dolan D; Ingham J; Baombe J
    Emerg Med J; 2020 Jul; 37(7):450-451. PubMed ID: 32616658
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.
    Pereda R; González D; Rivero HB; Rivero JC; Pérez A; López LDR; Mezquia N; Venegas R; Betancourt JR; Domínguez RE
    J Interferon Cytokine Res; 2020 Sep; 40(9):438-442. PubMed ID: 32960147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.
    Hong SI; Ryu BH; Chong YP; Lee S; Kim S; Kim HC; Hong KW; Bae IG; Cho OH
    Int J Antimicrob Agents; 2020 Aug; 56(2):106052. PubMed ID: 32544570
    [No Abstract]   [Full Text] [Related]  

  • 13. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
    Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
    Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.
    Wang B; Li D; Liu T; Wang H; Luo F; Liu Y
    BMC Infect Dis; 2020 Oct; 20(1):723. PubMed ID: 33008327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.
    Dalili N; Kashefizadeh A; Nafar M; Poorrezagholi F; Firouzan A; Samadian F; Samavat S; Ziaie S; Fatemizadeh S
    Trials; 2020 Jun; 21(1):489. PubMed ID: 32503620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.
    Xie X; Jiang Y; Zeng Y; Liu H
    Antivir Ther; 2020; 25(4):233-239. PubMed ID: 32496210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
    Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection of severe acute respiratory syndrome coronavirus 2 in a patient with AIDS.
    Su J; Shen X; Ni Q; Zhao H; Cai J; Zhu B; Wu W; Lang G; Xu K; Sheng J
    AIDS; 2020 Aug; 34(10):1575-1576. PubMed ID: 32675569
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.
    Wang Z; Chen X; Lu Y; Chen F; Zhang W
    Biosci Trends; 2020 Mar; 14(1):64-68. PubMed ID: 32037389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lopinavir pharmacokinetics in COVID-19 patients.
    Gregoire M; Le Turnier P; Gaborit BJ; Veyrac G; Lecomte R; Boutoille D; Canet E; Imbert BM; Bellouard R; Raffi F
    J Antimicrob Chemother; 2020 Sep; 75(9):2702-2704. PubMed ID: 32443151
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.